We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Estrogen and Progesterone Receptor Guideline for Tamoxifen Therapy in Chronic Lymphocytic Leukemia: A Pilot Study.
- Authors
Zaniboni, A.; Lorenzo, Di; Simoncini, E.; Marpicati, P.; Gorni, F.; Marini, G.; Marinone, G..
- Abstract
We studied estrogen and progesterone receptors (ER, PR) in 23 patients with chronic lymphocytic leukemia (CLL) and evaluated the results of this determination with other clinical and laboratory parameters. ER and PR activity was found respectively in 12 out of 23 (52%) and 6 out of 23 (26%) of the patients with a range between 2 and 23 fmol/mg protein (mean 10.3 fmol/mg) for ER and 18 and 92 fmol/mg (mean 41.8 fmol/mg) for PR. No correlations between ER/PR status and other parameters such as age, sex, stage, androgen and glucorticoid receptors (AR, GR), lymphocytic count or plasma estradiol and progesterone levels were noted. Seventeen consecutive patients out of 23 with a known receptor status and 1 with an unknown receptor status had been treated with tamoxifen 30 mg/day for 3 months. No objective response was achieved, despite some occasional reports of the literature. Copyright © 1986 S. Karger AG, Basel
- Publication
Acta Haematologica, 1986, Vol 75, Issue 2, p92
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000206093